MONTREAL, CANADA--(Marketwire - September 17, 2008) - ART Advanced Research Technologies Inc. (“ART”) (TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, announced today that it has shipped the first of two Optix® MX2 units ordered by the National Cancer Institute - Frederick (NCI-Frederick), in Maryland, USA.
